Purchase this article with an account.
E.Y. Chew, F.L. Ferris, F.M. de Monasterio, D.J. Thompson, J. Kim, C.G. Csaky, M. Woods, F. Khachik, R. Bone, J. Landrum; Dose Ranging Study of Lutein Supplementation in Persons Over Age 60 . Invest. Ophthalmol. Vis. Sci. 2003;44(13):968.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:To evaluate the association of varying doses of oral supplementation of lutein with the plasma levels of lutein in people over age 60 with and without age-related macular degeneration (AMD). Methods: Fifteen patients with small drusen, 15 with large drusen, and 15 with advanced AMD (neovascular or geographic atrophy) were randomly assigned to receive one of three oral daily doses of lutein, 2.5 mg, 5 mg, and 10 mg for 6 months with additional post-supplementation follow-up for 6 months. Serum levels of lutein were measured at baseline, and 1, 3, 6, 9, and 12 months. At each vist, an eye exam and a heterochromatic flicker test of the optical density of the macular pigment were performed. Results: 33 women and 12 men aged 60 to 91 (average 71) years, were enrolled. Serum lutein levels increased at 1 month and peaked by 3 months of supplementation. When the lutein was discontinued, all serum lutein levels returned to near pretreatment values. The table below lists the median percent increase from baseline for each group. No adverse effects were observed that could be attributed to lutein supplementation. Visual acuity remained essentially unchanged during the 6-month dosing period. At baseline, heterochromatic flicker estimates of macular pigment density were observably lower in the end stage AMD group compared with the others. However, there were no large changes in estimated macular pigment density within or between groups during the supplementation period. Conclusions: A dose response relationship exists between oral lutein supplementation and serum lutein levels. No adverse experiences were attributed to the lutein supplementation up to10 mg/d. Other epidemiologic evidence suggests that lutein may play an important role in the treatment of age-related macular degeneration. A large cohort study of oral supplementation with adequate sample size is needed to investigate the potential and long-term treatment effects of lutein for AMD. View OriginalDownload SlideView OriginalDownload Slide
This PDF is available to Subscribers Only